Faecal calprotectin (FC) is now part of the new official European Crohn’s and Colitis Organisation (ECCO) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) guidelines.
The #1 Resource for Calprotectin in the UK and Eire
- digestivedx@alphalabs.co.uk
- +44 (0) 23 8048 3000
Author: Webmaster
The New Faecal Calprotectin Care Pathway, developed by Dr James Turvill, Consultant Gastroenterologist at York Teaching Hospitals NHS Foundation Trust, and implemented by the Yorkshire and Humber AHSN, supports the implementation of NICE guidance DG11, for the detection of inflammation in the bowel (i.e. IBS vs IBD). The innovative and sensitive pathway based will help
A report from BIVDA and Innovate UK has identified that wider use of some IVD tests could save money and improve patient care. As we celebrate the 70th anniversary of the NHS is this one way to strengthen its future? Calprotectin is one of the tests identified in the report. It is already utilised in the NHS,
Calprotectin Testing Goes Mobile With advances in technology and the ubiquitous use of mobile devices, a huge opportunity has arisen to change the way some healthcare services are provided. This is especially applicable to the management of chronic conditions. With most people owning a mobile device or tablet this becomes a convenient way for patients to
On 4th December 2017 the National Institute for Health and Care Excellence issued a Medtech Innovation Briefing [MIB132]: ‘Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease’. This describes the innovative aspect that test results can be acted on more quickly than waiting for standard laboratory tests and could help reduce colonoscopies and clinical appointments. Costs may
The RCGP, in partnership with Crohn’s and Colitis UK, has launched an IBD toolkit for GPs and healthcare professionals. Clinical Champion for Inflammatory Bowel Disease, Dr Kevin Barrett, developed the toolkit with the patient representative Rachel Fowler and the project’s steering group. He comments “Inflammatory Bowel Disease affects at least 1 in 250 of the
BÜHLMANN application specialist Christina Gabris has recently visited the UK to validate some new instrument protocols for the fCAL turbo assay. Christina spent time in hospitals around Newcastle to optimise CE marked protocols for the Beckman AU5800 and AU680. The range of instruments with CE marked protocols for fCAL turbo has now been expanded to 28 including: Roche: cobas c501 & c502, cobas c701
Labs are receiving increasing faecal calprotectin tests requests since NICE published Diagnostic Guideline 11: ‘Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel’. This recommends faecal calprotectin as a first-line test for patients presenting with gastrointestinal (GI) symptoms indicative of IBS or IBD. Pam Bowe, team manager in the Department of Biochemistry at the Cumberland Infirmary, describes the evolution of her laboratory procedures to cope
Read about the work at Luton and Dunstable University Hospital, where Louise Asser and her colleagues have been using small bowel capsule endoscopy, to review patients with an increased calprotectin but normal colonoscopy, to investigate them for small bowel pathology and re-evaluate presumed false positive calprotectin results.
We are now taking bookings for this year’s Diagnostics for Digestive Health Seminar. The event takes place on 17 October 2013 at the Academy of Medical Sciences, Portland Place, London. The draft agenda is below, and the event is worth 7 IBMS CPD points and 6 RcPath CPD points.
